Metabolic Aspects of Citrate Anticoagulation in Renal Replacement Therapy

Charles University, Czech Republic

Status: Unknown

Conditions: Critical Illness; Acute Renal Failure

Study type: Observational

Funder types: Other

Identifiers

NCT01361581

NS/10014-4

Details and patient eligibility

About

Citrate anticoagulation is associated with metabolic side effects which are linked to a portion of citrate reaching systemic circulation. Data on significance of systemic gain of citrate and its relationship to method configuration are missing. Patient might also receive certain dose of lactate as a buffer and a dose of glucose if acid-citrate-dextrose solution is used. The authors test variable methods of indirect estimate of systemic dose of citrate which would allow to quantify the metabolic input without mostly unavailable measurements of citrate levels.

Enrollment: 120 estimated patients

Sex: All

Ages: 16+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Acute renal failure on continuous renal replacement therapy for more than 24 hours (CVVH or CVVHDF).

Exclusion criteria

• Absence of consent.

Trial design

120 participants in 3 patient groups

ACD (acid-citrate-dextrose)

4% trisodium citrate

unfractionated heparin (UFH)